



Press release Stockholm 2025-03-07 08:00 CET

## **Kancera announces intention to change company name to Novakand Pharma**

**Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company's strategic decision to focus on cardiovascular diseases.**

*"The current company name Kancera goes back to when the company was established and had a strong focus on cancer. Changing the company name is a logical step, in the light of our recent strategic decision to focus on cardiovascular diseases,"* says Peter Selin, CEO of Kancera.

The formal decision to change the company name will be made at the Annual General Meeting on May 26, 2025.

### **About Kancera AB (publ)**

Kancera is developing a new class of anti-inflammatory drugs in the field of cardiovascular diseases. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

### **For further information:**

Visit Kancera's website: [www.kancera.com](http://www.kancera.com)

### **or contact:**

ir@kancera.com or phone: +46 (0)8-5012 60 80